RECURSION PHARMACEUTICALS, INC. 4

Chief Scientific Officer David Hallett had 26,657 RXRX Class A shares withheld for taxes in connection with RSU settlement, leaving him with 1,043,837 shares.

On August 17, 2026, Recursion Pharmaceuticals, Inc. Chief Scientific Officer David Hallett had 26,657 shares of Class A common stock withheld by the company at an implied price of $3.16 per share, for an estimated value of about $84,000, to cover tax withholding obligations arising from the net settlement of previously granted restricted stock units. This Form 4 reflects a non-discretionary, compensation-related share withholding transaction rather than an open-market trade, and following the withholding Mr. Hallett continued to hold 1,043,837 shares of Class A common stock.

Filing Facts

CIK

1601830

Ticker

RXRX

Form

4

Source Type

fda

Accession

0002006495-26-000012

Alert Tier

5